Literature DB >> 35389238

Use of the Hollow-Fiber Infection Model to Measure the Effect of Combination Therapy of Septic Shock Exposures of Meropenem and Ciprofloxacin against Intermediate and Resistant Pseudomonas aeruginosa Clinical Isolates.

Natalija Karabasevic1, Jason A Roberts2,3,4,5, Luke Stronach2, Saiyuri Naicker2,3, Steven C Wallis3, Fredrik Sjövall6,7, Fekade Sime2,3.   

Abstract

Meropenem-ciprofloxacin combination therapy was compared to the respective monotherapy in a Hollow-Fiber Infection Model against two Pseudomonas aeruginosa isolates. Following initial kill of ∼ 5-logs by each monotherapy, rapid regrowth occurred within 24 h, reaching 108 - 1010 CFU/mL at 120 h. In contrast, combination therapy achieved > 5-log kill within 6 h and suppressed bacterial regrowth throughout. The results suggest that meropenem-ciprofloxacin combination may provide significantly enhanced bacterial killing and resistance suppression against P. aeruginosa.

Entities:  

Keywords:  Hollow-Fiber Infection Model; Pseudomonas aeruginosa; combination therapy

Mesh：

Substances：

Year:  2022        PMID： 35389238      PMCID： PMC9112939          DOI： 10.1128/aac.02140-21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.938


  21 in total

1.  Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.

Authors:  Glenn A Pankuch; Gengrong Lin; Harald Seifert; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-10-29       Impact factor: 5.191

Review 2.  β-lactam antibiotic versus combined β-lactam antibiotics and single daily dosing regimens of aminoglycosides for treating serious infections: A meta-analysis.

Authors:  Aaron James Heffernan; Fekade Bruck Sime; Jing Sun; Jeffrey Lipman; Anand Kumar; Katherine Andrews; David Ellwood; Keith Grimwood; Jason Roberts
Journal:  Int J Antimicrob Agents       Date:  2019-11-05       Impact factor: 5.283

3.  Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.

Authors:  Andrew Rhodes; Laura E Evans; Waleed Alhazzani; Mitchell M Levy; Massimo Antonelli; Ricard Ferrer; Anand Kumar; Jonathan E Sevransky; Charles L Sprung; Mark E Nunnally; Bram Rochwerg; Gordon D Rubenfeld; Derek C Angus; Djillali Annane; Richard J Beale; Geoffrey J Bellinghan; Gordon R Bernard; Jean-Daniel Chiche; Craig Coopersmith; Daniel P De Backer; Craig J French; Seitaro Fujishima; Herwig Gerlach; Jorge Luis Hidalgo; Steven M Hollenberg; Alan E Jones; Dilip R Karnad; Ruth M Kleinpell; Younsuk Koh; Thiago Costa Lisboa; Flavia R Machado; John J Marini; John C Marshall; John E Mazuski; Lauralyn A McIntyre; Anthony S McLean; Sangeeta Mehta; Rui P Moreno; John Myburgh; Paolo Navalesi; Osamu Nishida; Tiffany M Osborn; Anders Perner; Colleen M Plunkett; Marco Ranieri; Christa A Schorr; Maureen A Seckel; Christopher W Seymour; Lisa Shieh; Khalid A Shukri; Steven Q Simpson; Mervyn Singer; B Taylor Thompson; Sean R Townsend; Thomas Van der Poll; Jean-Louis Vincent; W Joost Wiersinga; Janice L Zimmerman; R Phillip Dellinger
Journal:  Intensive Care Med       Date:  2017-01-18       Impact factor: 17.440

4.  Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial.

Authors:  Frank M Brunkhorst; Michael Oppert; Gernot Marx; Frank Bloos; Katrin Ludewig; Christian Putensen; Axel Nierhaus; Ulrich Jaschinski; Andreas Meier-Hellmann; Andreas Weyland; Matthias Gründling; Onnen Moerer; Reimer Riessen; Armin Seibel; Maximilian Ragaller; Markus W Büchler; Stefan John; Friedhelm Bach; Claudia Spies; Lorenz Reill; Harald Fritz; Michael Kiehntopf; Evelyn Kuhnt; Holger Bogatsch; Christoph Engel; Markus Loeffler; Marin H Kollef; Konrad Reinhart; Tobias Welte
Journal:  JAMA       Date:  2012-06-13       Impact factor: 56.272

5.  Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis.

Authors:  Nasia Safdar; Jo Handelsman; Dennis G Maki
Journal:  Lancet Infect Dis       Date:  2004-08       Impact factor: 25.071

6.  Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates.

Authors:  Miguel López-Dupla; José-Antonio Martínez; Francesc Vidal; Manuel Almela; Alex Soriano; Francesco Marco; Josefina López; Montserrat Olona; Josep Mensa
Journal:  Am J Infect Control       Date:  2009-05-31       Impact factor: 2.918

7.  Fluoroquinolone Prophylaxis Selects for Meropenem-nonsusceptible Pseudomonas aeruginosa in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients.

Authors:  Morgan Hakki; Romney M Humphries; Peera Hemarajata; Gregory B Tallman; Ryan K Shields; Roberta T Mettus; Yohei Doi; James S Lewis
Journal:  Clin Infect Dis       Date:  2019-05-30       Impact factor: 9.079

8.  Cross-resistance to meropenem, cephems, and quinolones in Pseudomonas aeruginosa.

Authors:  N Masuda; S Ohya
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

9.  Influence of empirical double-active combination antimicrobial therapy compared with active monotherapy on mortality in patients with septic shock: a propensity score-adjusted and matched analysis.

Authors:  Marco Ripa; Olga Rodríguez-Núñez; Celia Cardozo; Antonio Naharro-Abellán; Manel Almela; Francesc Marco; Laura Morata; Cristina De La Calle; Ana Del Rio; Carolina Garcia-Vidal; María Del Mar Ortega; María De Los Angeles Guerrero-León; Csaba Feher; Berta Torres; Pedro Puerta-Alcalde; Josep Mensa; Alex Soriano; José Antonio Martínez
Journal:  J Antimicrob Chemother       Date:  2017-12-01       Impact factor: 5.790

Review 10.  Combination antibiotic therapy for multidrug-resistant Gram-negative bacteria.

Authors:  Thomas Tängdén
Journal:  Ups J Med Sci       Date:  2014-03-26       Impact factor: 2.384
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.